glp-1-ra Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Emerging Trends in the Development

MT-1's mechanism requires concurrent UV stimulus to drive melanin synthesis

Study Finds Diabetes Medication Reduces Risk Of Death And Heart Disease In People With Arthritis August 12, 2024 (Vancouver) A study conducted by Arthritis Research Canada has revealed that certain diabetes medications, specifically glucagon-like peptide-1 receptor agonists (GLP-1-RAs) like semaglutide (Ozempic), reduced the risk of death and heart attacks in people with immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis, psoriasis, and lupus, who also have type 2 diabetes

As of July 1, 2025, CVS Caremark selected Wegovy as its preferred weight loss medication, removing Zepbound from most formularies

[DOI] [PubMed] [Google Scholar] 97.Heinrichs M., Baumgartner T., Kirschbaum C., Ehlert U

Available online at: 226